See feature article below: Clovis Oncology Inc (NASDAQ: CLVS)
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 568% in verifiable potential gains for our members on 2 recent small cap alerts alone!
May 9th, 2016-(NYSE-MKT: MGT) opened at .64/share and hit $4.15/share within 8 days for potential gains of 548% for our members.
May 23rd, 2016 (NYSE-MKT: XXII) opened at $.78/share and hit $.94/share within 2 days for potential gains of 20% for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Next PDUFA Date 06/28/2016
BOULDER, Colo. – Clovis Oncology (CLVS) is facing a federal probe over data regarding its cancer drug, rociletinib. The probe centers on an announcement the company made last year that data showed a reduced rate of complete tumor responses.
In its 10-Q filing with the U.S. Securities and Exchange Commission, Clovis said both immature confirmed and unconfirmed response analyses were submitted to federal regulators. In its filing though, Clovis did not specify which federal body was involved in the probe. In the filing, Clovis said it was cooperating with the inquiries.
In November, Clovis announced that it used interim data about the efficacy of rociletinib publicly and at medical meetings. In its New Drug Application with the U.S. Food and Drug Administration , Clovis said it also used the interim data.
“As the efficacy data have matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected,” Clovis said in November.
The FDA asked Clovis to submit additional data about its efficacy. Clovis had expecting the FDA to rule on rociletinib sometime earlier this year, but the data request pushed that back to April, when ultimately an FDA panel recommended against giving rociletinib an accelerated approval. More recently, Clovis said it met with the FDA and was told it would receive a Complete Response Letter regarding the drug on or before the June 28 deadline for the regulatory agency to rule on a new drug. A Complete Response Letter is issued by the FDA to notify a company that its new drug is not ready for approval.
As a result of the Complete Response Letter, Colorado-based Clovis said it was stopping enrollment in all ongoing sponsored clinical studies of rociletinib. However, the company did say it would continue to provide the drug to patients whose clinicians recommend continuing rociletinib therapy. Based on the Complete Response Letter, Clovis said it was also withdrawing its request for regulatory approval of rociletinib by the European Medicines Agency.
Since November, Clovis stock has bottomed out, dropping from $106.20 per share to today’s price of $12.35 per share. Zack’s Investment Research lowered its rating of Clovis stock from a buy to a hold earlier this month.
With the termination of rociletinib, Clovis announced earlier this month that it will reduce its workforce by 35 percent, including full-time employees as well as contractors. Clovis said it will also halt any planned hiring activities. The terminations are expected to be complete by the end of the year.
The loss of the rociletinib program is a huge blow to Clovis, which does not have any approved products. Rociletinib was the lead drug candidate in the company pipeline.
Not only is the company facing a federal probe, a Colorado law firm, the Shuman Law Firm, announced that it too had launched an investigation into Clovis about whether members of the company’s leadership “breached their fiduciary duties to the company by allegedly causing the Company to issue materially false and misleading statements regarding rociletinib.”
Several shareholders have filed complaints with the company over the cancer drug data. In its 10-Q filing, Clovis highlighted more than a dozen complaints against the company.
Source – Bio Space & BioPharma Catalyst
Broadstreetalerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. SCS LLC has been compensated twenty thousand dollars cash via bank wire by star media llc for a two day investor relations campaign of STEM. SCS LLC does not hold any positions in STEM. SCS LLC has previously been compensated twenty thousand dollars cash via bank wire by DF Media for the mention of MGT. We do not hold any positions in MGT. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. We have not been compensated nor do we own positions in the company/companies that are in the featured article.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
Please Note: We do NOT accept free trading or restricted securities as payment for our services.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.